Please ensure Javascript is enabled for purposes of website accessibility

Why Biogen's Q4 Results Were a Bust

By Keith Speights - Feb 3, 2021 at 11:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's 2021 guidance was the worst news of all with its Q4 update.

You can almost always know how strong a company's near-term prospects are by looking at its stock price. Biogen's (BIIB 3.28%) shares sank more than 17% last year while the overall market soared, reflecting significant investor pessimism. However, the stock is up solidly so far in 2021. That's a good sign that investors' confidence has increased.

But that optimism could take a hit after Biogen reported its fourth-quarter results before the market opened on Wednesday. Here are the highlights from the biotech's Q4 update.

Scientist looking through microscope in lab.

Image source: Getty Images.

By the numbers

Biogen's bad news started on the top line. The company reported revenue in the fourth quarter of $2.85 billion, down 22% year over year. However, this result narrowly topped the average analyst estimate of $2.8 billion.

The biotech announced fourth-quarter net income of $358 million, or $2.32 per share, based on generally accepted accounting principles (GAAP). This represented a sharp decline from its GAAP earnings of $1.4 billion, or $8.08 per share, recorded in the prior-year period. 

On an adjusted basis, Biogen's net income in the fourth quarter totaled $706 million, or $4.58 per share. This was a lot lower than the company's adjusted earnings of $1.5 billion, or $8.34 per share, posted in the fourth quarter of 2019. It also came in well below the consensus Wall Street adjusted earnings estimate of $4.87 per share.

Behind the numbers

Biogen CEO Michel Vounatsos referred to 2020 as "a challenging year" for the company. The biotech's Q4 results underscored just how challenging it was.

In the past, Biogen could count on its multiple sclerosis (MS) franchise for solid growth. That's no longer the case. The company reported total MS revenue fell 24% year over year to $1.8 billion, brought down by plunging sales for Tecfidera and Avonex. 

Until recently, Spinraza also served as a key growth driver for Biogen. However, in the fourth quarter sales of the spinal muscular atrophy drug slipped 8% year over year to $498 million.

Biogen's revenue from biosimilars increased in the fourth quarter, but not by much. Total biosimilar sales increased 1% year over year to $197 million. And even that growth was boosted by currency fluctuations. On a constant-currency basis, the company's biosimilar revenue decreased by 4%.

The biotech's bottom-line deterioration was primarily caused by its revenue decline. However, Biogen's research and development costs also skyrocketed nearly 150%. Most of this increase resulted from a charge of over $1 billion related to Biogen's collaboration with Sage Therapeutics.

Looking ahead

Biogen expects revenue for full-year 2021 will be between $10.45 billion and $10.75 billion. The company anticipates adjusted EPS between $17 and $18.50. Both guidance ranges reflect steep year-over-year declines.

Vounatsos said that the company "expect[s] a financial reset in 2021 primarily due to the entry of Tecfidera generics." But the biotech stock still has a major potential catalyst that could change its trajectory. Vounatsos added that Biogen thinks that 2021 could be "transformative year" for its pipeline.

In particular, he noted the anticipated U.S. Food and Drug Administration (FDA) decision on Alzheimer's disease candidate aducanumab in June. This almost certainly will be the most important FDA decision to watch this year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$210.63 (3.28%) $6.69
Sage Therapeutics, Inc. Stock Quote
Sage Therapeutics, Inc.
SAGE
$32.28 (-0.06%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.